FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / J Vet Intern Med / A randomized, masked, crossover, clinical trial of the effic...
Journal of veterinary internal medicine2026; 40(2); aalag030; doi: 10.1093/jvimsj/aalag030

A randomized, masked, crossover, clinical trial of the efficacy and safety of nebulized albuterol sulfate and dexamethasone sodium phosphate in asthmatic horses.

Abstract: Nebulization of injectable dexamethasone sodium phosphate (DSP; 0.01 mg/kg) to horses with severe equine asthma (SEA) was previously found to be ineffective. Horses with SEA have marked bronchoconstriction that decreases peripheral lung deposition of nebulized drugs. Administration of a bronchodilator immediately before nebulizing dexamethasone may improve efficacy. Objective: Evaluate the therapeutic effects and optimal dose of nebulized DSP after nebulized albuterol in horses with SEA. Methods: Seven horses with SEA from a research herd. Methods: In this masked randomized crossover trial, horses were assigned to one of 3 treatment groups: (1) 0.04 mg/kg DSP IV; (2) 0.01 mg/kg DSP by nebulization; and (3) 0.02 mg/kg DSP by nebulization, in a 3 × 3 Latin square design. All horses were treated q24h for 7 days and received albuterol (0.3 μg/kg) 10 min before DSP. Clinical score, pulmonary function testing, bronchoalveolar lavage fluid (BALF) cytology, adrenocorticotropic hormone stimulation test, plasma and BALF DSP concentrations and routine blood test results were compared between groups and over time. Results: Nebulized DSP resulted in similar lung deposition as IV DSP but did not suppress adrenocortical function. However, nebulized DSP did not improve clinical signs, lung function, or BALF cytology. Only IV DSP improved lung function. None of the treatments performed influenced BALF neutrophil proportions. Conclusions: Nebulization of albuterol before DSP minimizes systemic absorption of dexamethasone and preserves adrenal function of horses with SEA. Our results do not support the use of nebulized DSP at the doses used for the treatment of SEA.
© The Author(s) 2026. Published by Oxford University Press on behalf of the American College of Veterinary Internal Medicine.
Get Full Text
Publication Date: 2026-03-06 PubMed ID: 41789550PubMed Central: PMC12963962DOI: 10.1093/jvimsj/aalag030Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article
  • Randomized Controlled Trial
  • Veterinary
  • Randomized Controlled Trial
  • Clinical Trial
  • Veterinary

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

Overview

  • This clinical trial investigated whether administering a bronchodilator (albuterol) before nebulizing dexamethasone sodium phosphate (DSP) would improve the treatment of severe equine asthma (SEA) in horses.
  • The study compared different doses and routes of DSP administration to evaluate their effects on lung function, clinical signs, immune response, and safety.

Background

  • Severe equine asthma (SEA) is a chronic respiratory condition in horses marked by bronchoconstriction, inflammation, and difficulty breathing.
  • Previous research indicated that nebulized DSP at 0.01 mg/kg was ineffective, likely because bronchoconstriction limits the peripheral lung deposition of nebulized drugs.
  • Hypothesis: Administering a bronchodilator (albuterol) before nebulizing DSP could open airways and improve drug delivery to the lungs, enhancing treatment efficacy.

Study Design and Methods

  • Seven SEA-affected horses from a research herd participated in a randomized, masked crossover clinical trial with a 3×3 Latin square design.
  • The three treatment regimens were:
    • Intravenous (IV) DSP at 0.04 mg/kg
    • Nebulized DSP at 0.01 mg/kg
    • Nebulized DSP at 0.02 mg/kg
  • Before administering DSP, all horses were nebulized with albuterol at 0.3 μg/kg 10 minutes earlier to open airways.
  • Treatments were given once every 24 hours for 7 days per treatment period.
  • Several parameters were measured to assess treatment efficacy and safety:
    • Clinical scores reflecting respiratory signs
    • Pulmonary function tests measuring lung mechanics
    • Bronchoalveolar lavage fluid (BALF) cytology to evaluate airway inflammation
    • Adrenocorticotropic hormone (ACTH) stimulation test to check adrenal gland function
    • Measurements of DSP concentration in plasma and BALF to study drug deposition and absorption
    • Routine blood tests to detect systemic effects or adverse reactions

Key Findings

  • Nebulized DSP (both 0.01 and 0.02 mg/kg) achieved similar lung deposition levels compared to IV administration, indicating that albuterol improved drug delivery to some extent.
  • Nebulized DSP did not suppress adrenal function, as shown by the preserved response in the ACTH stimulation test, implying minimal systemic absorption.
  • Despite adequate lung deposition, nebulized DSP did not improve clinical respiratory signs, lung function measures, or reduce airway inflammation assessed by BALF cytology.
  • Only IV DSP at 0.04 mg/kg led to improvements in lung function, demonstrating it was the only effective treatment in this trial.
  • None of the treatment protocols had an effect on neutrophil proportions in the BALF, indicating persistent inflammation unaffected by DSP nebulization.

Conclusions and Clinical Implications

  • Using albuterol nebulization before DSP enhances lung deposition of nebulized DSP without causing systemic side effects or adrenal suppression.
  • However, nebulized DSP at the studied doses (0.01 and 0.02 mg/kg) does not improve lung function or clinical outcomes in SEA horses.
  • IV DSP remains the more effective approach for improving lung function in SEA, but with associated systemic corticosteroid effects.
  • The findings suggest that nebulized corticosteroid treatment may require different dosing strategies or formulations to be therapeutically effective.
  • Clinicians should be cautious about relying on nebulized DSP at these doses for SEA treatment, as efficacy was not demonstrated despite good lung delivery.

Cite This Article

APA
Tyson KN, Couetil LL, Ivester KM, Murray L, Mukhopadhyay A, Marmolejo JF, Jannasch A. (2026). A randomized, masked, crossover, clinical trial of the efficacy and safety of nebulized albuterol sulfate and dexamethasone sodium phosphate in asthmatic horses. J Vet Intern Med, 40(2), aalag030. https://doi.org/10.1093/jvimsj/aalag030

Publication

Journal of veterinary internal medicine
ISSN: 1939-1676
NlmUniqueID: 8708660
Country: United States
Language: English
Volume: 40
Issue: 2
PII: aalag030

Researcher Affiliations

Tyson, Kira N
  • Department of Veterinary Clinical Sciences, Purdue University College of Veterinary Medicine, West Lafayette, IN 47907, United States.
Couetil, Laurent L
  • Department of Veterinary Clinical Sciences, Purdue University College of Veterinary Medicine, West Lafayette, IN 47907, United States.
Ivester, Kathleen M
  • Department of Veterinary Clinical Sciences, Purdue University College of Veterinary Medicine, West Lafayette, IN 47907, United States.
Murray, Laura
  • Department of Veterinary Clinical Sciences, Purdue University College of Veterinary Medicine, West Lafayette, IN 47907, United States.
Mukhopadhyay, Abhijit
  • Department of Veterinary Clinical Sciences, Purdue University College of Veterinary Medicine, West Lafayette, IN 47907, United States.
Marmolejo, Jackeline Franco
  • Metabolite Profiling Facility, Bindley Bioscience Center, Purdue University, West Lafayette, IN 47907, United States.
Jannasch, Amber
  • Metabolite Profiling Facility, Bindley Bioscience Center, Purdue University, West Lafayette, IN 47907, United States.

MeSH Terms

  • Animals
  • Horses
  • Albuterol / therapeutic use
  • Albuterol / administration & dosage
  • Albuterol / adverse effects
  • Dexamethasone / analogs & derivatives
  • Dexamethasone / administration & dosage
  • Dexamethasone / therapeutic use
  • Dexamethasone / adverse effects
  • Horse Diseases / drug therapy
  • Asthma / drug therapy
  • Asthma / veterinary
  • Cross-Over Studies
  • Bronchodilator Agents / therapeutic use
  • Bronchodilator Agents / administration & dosage
  • Bronchodilator Agents / adverse effects
  • Female
  • Male
  • Nebulizers and Vaporizers / veterinary
  • Administration, Inhalation
  • Bronchoalveolar Lavage Fluid / cytology

Grant Funding

  • Nortev Ltd. Galway, Ireland
  • Indiana and the Purdue University College of Veterinary Medicine

Conflict of Interest Statement

Nortev Ltd. provided some funding to help support 2 workshops on equine asthma organized by Dr. Laurent Couetil (2019 and 2023). The other authors declare no conflicts of interest.

References

This article includes 42 references
  1. Robinson NE, Derksen FJ, Olszewski MA, BuechnerMaxwell VA. The pathogenesis of chronic obstructive pulmonary disease of horses.. Rev Br Vet J 1996;152:283-306.
    doi: 10.1016/s0007-1935(96)80101-1pubmed: 8762605google scholar: lookup
  2. Leclere M, Lavoie-Lamoureux A, Gelinas-Lymburner E, David F, Martin JG, Lavoie JP. Effect of antigenic exposure on airway smooth muscle Remodeling in an equine model of chronic asthma.. Am J Resp Cell Mol Biol 2011;45:181-187.
    doi: 10.1165/rcmb.2010-0300OCpubmed: 20935189google scholar: lookup
  3. Ivester KM, Couetil LL. Management of chronic airway inflammation in the horse: a systematic review.. Equine Vet Educ 2014;26:647-656.
    doi: 10.1111/eve.12238google scholar: lookup
  4. Couetil LL, Cardwell JM, Gerber V, Lavoie JP, Leguillette R, Richard EA. Inflammatory airway disease of horses—revised consensus statement.. J Vet Intern Med 2016;30:503-515.
    doi: 10.1111/jvim.13824pmc: PMC4913592pubmed: 26806374google scholar: lookup
  5. Calzetta L, Rogliani P, Page C. Clinical effect of corticosteroids in asthma-affected horses: a quantitative synthesis.. Equine Vet J 2018;50:594-601.
    doi: 10.1111/evj.12815pubmed: 29393535google scholar: lookup
  6. Leclere M, Lefebvre-Lavoie J, Beauchamp G, Lavoie JP. Efficacy of oral prednisolone and dexamethasone in horses with recurrent airway obstruction in the presence of continuous antigen exposure.. Equine Vet J 2010;42:316-321.
    doi: 10.1111/j.2042-3306.2009.00022.xpubmed: 20525049google scholar: lookup
  7. Cuming RS, Groover ES, Wooldridge AA, Caldwell FJ. Review of glucocorticoid therapy in horses. Part 1: pharmacology.. Rev Equine Vet Educ 2018;30:141-150.
    doi: 10.1111/eve.12555google scholar: lookup
  8. Mair TS. Bacterial pneumonia associated with corticosteroid therapy in three horses.. Vet Rec 1996;138:205-207.
    doi: 10.1136/vr.138.9.205pubmed: 8686153google scholar: lookup
  9. Slack J, Risdahl JM, Valberg SJ, Murphy MJ, Schram BR, Lunn DP. Effects of dexamethasone on development of immunoglobulin G subclass responses following vaccination of horses.. Am J Vet Res 2000;61:1530-1533.
    doi: 10.2460/ajvr.2000.61.1530pubmed: 11131594google scholar: lookup
  10. Lepage OM, Laverty S, Marcoux M, Dumas G. Serum osteocalcin concentration in horses treated with triamcinolone acetonide.. Am J Vet Res 1993;54:1209-1212.
    pubmed: 8214885
  11. Cornelisse CJ, Robinson NE. Glucocorticoid therapy and the risk of equine laminitis.. Rev Equine Vet Educ 2013;25:39-46.
    doi: 10.1111/j.2042-3292.2011.00320.xgoogle scholar: lookup
  12. Couetil LL, Ward MP. Analysis of risk factors for recurrent airway obstruction in north American horses: 1,444 cases (1990-1999).. J Am Vet Med Assoc 2003;223:1645-1650.
    doi: 10.2460/javma.2003.223.1645pubmed: 14664454google scholar: lookup
  13. Haspel AD, Giguere S, Hart KA, Berghaus LJ, Davis JL. Bioavailability and tolerability of nebulised dexamethasone sodium phosphate in adult horses.. Equine Vet J 2018;50:85-90.
    doi: 10.1111/evj.12724pubmed: 28719014google scholar: lookup
  14. Mainguy-Seers S, Bessonnat A, Picotte K, Lavoie JP. Nebulisation of dexamethasone sodium phosphate for the treatment of severe asthmatic horses.. Equine Vet J 2019;51:641-645.
    doi: 10.1111/evj.13091pubmed: 30849189google scholar: lookup
  15. de Wasseige S, Picotte K, Lavoie JP. Nebulized dexamethasone sodium phosphate in the treatment of horses with severe asthma.. J Vet Intern Med 2021;35:1604-1611.
    doi: 10.1111/jvim.16113pmc: PMC8162592pubmed: 33817859google scholar: lookup
  16. Rush BR, Hoskinson JJ, Davis EG, Matson CJ, Hakala JE. Pulmonary distribution of aerosolized technetium Tc 99m pentetate after administration of a single dose of aerosolized albuterol sulfate in horses with recurrent airway obstruction. Am J Vet Res 1999;60:764-769.
    pubmed: 10376909
  17. Bertin FR, Ivester KM, Couetil LL. Comparative efficacy of inhaled albuterol between two hand-held delivery devices in horses with recurrent airway obstruction. Equine Vet J 2011;43:393-398.
    doi: 10.1111/j.2042-3306.2010.00313.xpubmed: 21496081google scholar: lookup
  18. Stewart AJ, Behrend EN, Wright JC. Validation of a low-dose ACTH stimulation test in healthy adult horses. J Am Vet Med Assoc 2011;239:834-841.
    pubmed: 21916767
  19. Chen XY, Wang SM, Li N. Creation of lung-targeted dexamethasone immunoliposome and its therapeutic effect on bleomycin-induced lung injury in rats. PloS One 2013;8:e58275.
    doi: 10.1371/journal.pone.0058275pmc: PMC3597622pubmed: 23516459google scholar: lookup
  20. Lavoie JP, Thompson D, Hamilton E, Debrue M, David F, Hickey G. Effects of a MAPK p38 inhibitor on lung function and airway inflammation in equine recurrent airway obstruction. Equine Vet J 2008;40:577-583.
    doi: 10.2746/042516408x284646pubmed: 19031513google scholar: lookup
  21. Picandet V, Leguillette R, Lavoie JP. Comparison of efficacy and tolerability of isoflupredone and dexamethasone in the treatment of horses affected with recurrent airway obstruction ('heaves'). Equine Vet J 2003;35:419-424.
    doi: 10.2746/042516403776014208pubmed: 12880012google scholar: lookup
  22. Mazan MR, Lascola K, Bruns SJ, Hoffman AM. Use of a novel one-nostril mask-spacer device to evaluate airway hyperresponsiveness (AHR) in horses after chronic administration of albuterol. Can J Vet Res 2014;78:214-220.
    pmc: PMC4068413pubmed: 24982553
  23. Funch-Nielsen H, Roberts C, Weekes J, Deaton C, Marlin D. Evaluation of a new spacer device for delivery of drugs into the equine respiratory tract. Proceedings of the WEAS-CRS Symposium 2001:56.
  24. Arroyo MG, Couetil LL, Nogradi N, Kamarudin MM, Ivester KM. Efficacy of inhaled levalbuterol compared to albuterol in horses with recurrent airway obstruction. J Vet Intern Med 2016;30:1333-1337.
    doi: 10.1111/jvim.14320pmc: PMC5089594pubmed: 27282625google scholar: lookup
  25. Soma LR, Uboh CE, Liu Y. Pharmacokinetics of dexamethasone following intra-articular, intravenous, intramuscular, and oral administration in horses and its effects on endogenous hydrocortisone. J Vet Pharmacol Ther 2013;36:181-191.
    doi: 10.1111/j.1365-2885.2012.01412.xpubmed: 22632064google scholar: lookup
  26. Earla R, Boddu SHS, Cholkar K, Hariharan S, Jwala J, Mitra AK. Development and validation of a fast and sensitive bioanalytical method for the quantitative determination of glucocorticoids-quantitative measurement of dexamethasone in rabbit ocular matrices by liquid chromatography tandem mass spectrometry. J Pharm Biomed Anal 2010;52:525-533.
    doi: 10.1016/j.jpba.2010.01.015pmc: PMC2853008pubmed: 20172680google scholar: lookup
  27. Rennard SI, Basset G, Lecossier D. Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution. J Appl Physiol 1986;60:532-538.
    pubmed: 3512509
  28. Fultz L, Giguere S, Berghaus LJ, Grover GS, Merritt DA. Pulmonary pharmacokinetics of desfuroylceftiofur acetamide after nebulization or intramuscular administration of ceftiofur sodium to weanling foals. In: Proceedings of the 60th Annual Convention of the American Association of Equine Practitioners, Salt Lake City, Utah, USA, December 6-10 2014. American Association of Equine Practitioners (AAEP); 2014.
    pubmed: 24975449
  29. Lavoie JP, Pasloske K, Joubert P. Lack of clinical efficacy of a phosphodiesterase-4 inhibitor for treatment of heaves in horses. J Vet Intern Med 2006;20:175-181.
    doi: 10.1892/0891-6640(2006)20[175:loceoa]2.0.co;2pubmed: 16496938google scholar: lookup
  30. Robinson NE, Jackson C, Jefcoat A, Berney C, Peroni D, Derksen FJ. Efficacy of three corticosteroids for the treatment of heaves. Equine Vet J 2002;34:17-22.
    doi: 10.2746/042516402776181105pubmed: 11817547google scholar: lookup
  31. Rush BR, Raub ES, Rhoads WS. Pulmonary function in horses with recurrent airway obstruction after aerosol and parenteral administration of beclomethasone dipropionate and dexamethasone, respectively.. Am J Vet Res 1998;59:1039-1043.
    pubmed: 9706210
  32. Lavoie JP, Leguillette R, Pasloske K. Comparison of effects of dexamethasone and the leukotriene D4 receptor antagonist L-708,738 on lung function and airway cytologic findings in horses with recurrent airway obstruction.. Am J Vet Res 2002;63:579-585.
    doi: 10.2460/ajvr.2002.63.579pubmed: 11939323google scholar: lookup
  33. Leclere M, Lavoie-Lamoureux A, Joubert P. Corticosteroids and antigen avoidance decrease airway smooth muscle mass in an equine asthma model.. Am J Respir Cell Mol Biol 2012;47:589-596.
    doi: 10.1165/rcmb.2011-0363OCpubmed: 22721832google scholar: lookup
  34. Robinson NE, Berney C, Behan A, Derksen FJ. Fluticasone propionate aerosol is more effective for prevention than treatment of recurrent airway obstruction.. J Vet Intern Med 2009;23:1247-1253.
    doi: 10.1111/j.1939-1676.2009.0382.xpubmed: 19747193google scholar: lookup
  35. Gerber V, Schott HC II, Robinson NE. Owner assessment in judging the efficacy of airway disease treatment.. Equine Vet J 2011;43:153-158.
    doi: 10.1111/j.2042-3306.2010.00156.xpubmed: 21592208google scholar: lookup
  36. Rush BR, Flaminio MJBF, Matson CJ, Hakala JE, Shuman W. Cytologic evaluation of bronchoalveolar lavage fluid from horses with recurrent airway obstruction after aerosol and parenteral administration of beclomethasone dipropionate and dexamethasone, respectively.. Am J Vet Res 1998;59:1033-1038.
    pubmed: 9706209
  37. Bond S, Léguillette R. A consort-guided, randomized controlled clinical trial of nebulized administration of dexamethasone and saline on lower airway cytokine mRNA expression in horses with moderate asthma.. J Vet Intern Med 2024;38:1214-1223.
    doi: 10.1111/jvim.16983pmc: PMC10937472pubmed: 38205666google scholar: lookup
  38. Pirie RS, Collie DD, Dixon PM, McGorum BC. Evaluation of nebulised hay dust suspensions (HDS) for the diagnosis and investigation of heaves. 2: effects of inhaled HDS on control and heaves horses.. Equine Vet J 2002;34:337-342.
    doi: 10.2746/042516402776249074pubmed: 12117104google scholar: lookup
  39. Pirie RS, Dixon PM, McGorum BC. Evaluation of nebulised hay dust suspensions (HDS) for the diagnosis and investigation of heaves. 3: effect of fractionation of HDS.. Equine Vet J 2002;34:343-347.
    doi: 10.2746/042516402776249236pubmed: 12117105google scholar: lookup
  40. Pirie RS, Dixon PM, McGorum BC. Endotoxin contamination contributes to the pulmonary inflammatory and functional response to extract inhalation in heaves horses.. Clin Exp Allergy 2003;33:1289-1296.
    doi: 10.1046/j.1365-2745.2003.01651.xpubmed: 12956737google scholar: lookup
  41. Rush BR, Worster AA, Flaminio MJBF, Matson CJ, Hakala JE. Alteration in adrenocortical function in horses with recurrent airway obstruction after aerosol and parenteral administration of beclomethasone dipropionate and dexamethasone, respectively.. Am J Vet Res 1998;59:1044-1047.
    pubmed: 9706211
  42. Kirschvink N, Fievez L, Dogne S, Bureau F, Art T, Lekeux P. Comparison of inulin with urea as dilutional markers of bronchoalveolar lavage in healthy and heaves-affected horses.. Vet Res 2001;32:145-154.
    pubmed: 11361150

Citations

This article has been cited 0 times.
Subscribe to our newsletter
Join 99,030 horse owners like you who receive our email updates on horse health and nutrition.